AMANDA RIVERA: Open Payments
NPI 1568973618 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$406 in 29 payments from 8 companies in 2025. Trend: 2023 $28 · 2024 $492 · 2025 $406
Food & beverage: $406
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $184 |
| Vanda Pharmaceuticals Inc. | 3 | $65 |
| E.R. Squibb & Sons, L.L.C. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Neurocrine BioSciences, Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Alkermes, Inc. | 1 | $15 |
Products named: VRAYLAR, FANAPT, COBENFY, HETLIOZ, ABILIFY ASIMTUFII, INGREZZA, AUSTEDO XR, Auvelity.
Industry payments across NY — which companies pay providers there.
